Table 1.
Clinical characteristics of study subjects (n = 129)
| Clinical characteristicsM | Mean ± SD |
|---|---|
| Age (years) |
45.7 ± 10.9 |
| Age of onset (years) |
24.6 ± 9.5 |
| Education (years) |
11.8 ± 3.3 |
| Latency to CBZ treatment (Years) |
10.8 ± 7.6 |
| Follow-up period after CBZ treatment (Years) |
10.4 ± 5.2 |
| Current CBZ dose (mg) |
571.3 ± 212.6 |
| Current CBZ plasma level (μg/mL) |
7.8 ± 5.9 |
| Mood episodes before CBZ treatment |
N (%) |
| 1 |
42 (32.6) |
| 2 |
22 (17.1) |
| 3 |
28 (21.7) |
| 4 |
16 (12.4) |
| ≧5 |
21 (16.3) |
| Mood episodes after CBZ treatment |
N (%) |
| 0 |
63 (48.8) |
| 1 |
21 (16.3) |
| 2 |
22 (17.1) |
| 3 |
6 (4.7) |
| ≧4 | 17 (13.2) |
CBZ carbamazepine.